Skip to content

NeoGenomics NEO Book value per share

Book value per share at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$65.77+7.3%
Personalis, Inc. logo
Personalis, Inc.PSNL
$2.45+3.1%
Guardant Health logo
Guardant HealthGH
-$1.38+31.9%
Natera, Inc. logo
Natera, Inc.NTRA
$12.54+36.3%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$2.33+21.6%
GeneDx Holdings logo
GeneDx HoldingsWGS
$8.66-5.3%

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B+86.5%
Enterprise value$1.6B+159%
P/S2.3×+0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Calculated from NeoGenomics’s reported figures.

Based on the most recent quarter.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's book value per share?
NeoGenomics (NEO) reported book value per share of $6.42 in Q1 2026.
How has NeoGenomics's book value per share changed year-over-year?
NeoGenomics's book value per share decreased by 8.0% year-over-year, from $6.97 to $6.42.
What is the long-term trend for NeoGenomics's book value per share?
Over 5 years (2020 to 2025), NeoGenomics's book value per share has grown at a 1.0% compound annual growth rate (CAGR), from $6.21 to $6.53.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.